Literature DB >> 23564636

Ibuprofen therapy resulted in significantly decreased tissue bacillary loads and increased survival in a new murine experimental model of active tuberculosis.

Cristina Vilaplana1, Elena Marzo, Gustavo Tapia, Jorge Diaz, Vanesa Garcia, Pere-Joan Cardona.   

Abstract

C3HeB/FeJ mice infected with Mycobacterium tuberculosis were used in an experimental animal model mimicking active tuberculosis in humans to evaluate the effect of antiinflammatory agents. No other treatment but ibuprofen was given, and it was administered when the animals' health started to deteriorate. Animals treated with ibuprofen had statistically significant decreases in the size and number of lung lesions, decreases in the bacillary load, and improvements in survival, compared with findings for untreated animals. Because antiinflammatory agents are already on the market, further clinical trials should be done to evaluate this effect in humans as soon as possible, to determine their suitability as coadjuvant tuberculosis treatment.

Entities:  

Keywords:  C3HeB/FeJ mice; active tuberculosis; antiinflammatory agents; bacillary load; ibuprofen; survival; tuberculosis; tuberculosis coadjuvant treatment; tuberculosis treatment

Mesh:

Substances:

Year:  2013        PMID: 23564636     DOI: 10.1093/infdis/jit152

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  81 in total

Review 1.  Antibiotic resistance breakers: can repurposed drugs fill the antibiotic discovery void?

Authors:  David Brown
Journal:  Nat Rev Drug Discov       Date:  2015-10-23       Impact factor: 84.694

Review 2.  Host-directed therapeutics for tuberculosis: can we harness the host?

Authors:  Thomas R Hawn; Alastair I Matheson; Stephen N Maley; Omar Vandal
Journal:  Microbiol Mol Biol Rev       Date:  2013-12       Impact factor: 11.056

3.  Treatment-Associated Inflammatory Deterioration in Tuberculous Meningitis: Unpicking the Paradox.

Authors:  Nguyen Thuy Thuong Thuong; Guy E Thwaites
Journal:  J Infect Dis       Date:  2017-03-01       Impact factor: 5.226

Review 4.  Disease tolerance and immunity in host protection against infection.

Authors:  Miguel P Soares; Luis Teixeira; Luis F Moita
Journal:  Nat Rev Immunol       Date:  2017-01-03       Impact factor: 53.106

Review 5.  Potential anti-TB investigational compounds and drugs with repurposing potential in TB therapy: a conspectus.

Authors:  Adetomiwa A Adeniji; Kirsten E Knoll; Du Toit Loots
Journal:  Appl Microbiol Biotechnol       Date:  2020-05-05       Impact factor: 4.813

Review 6.  New tricks for old dogs: countering antibiotic resistance in tuberculosis with host-directed therapeutics.

Authors:  Thomas R Hawn; Javeed A Shah; Daniel Kalman
Journal:  Immunol Rev       Date:  2015-03       Impact factor: 12.988

Review 7.  Host-Directed Therapies for Tuberculosis.

Authors:  David M Tobin
Journal:  Cold Spring Harb Perspect Med       Date:  2015-05-18       Impact factor: 6.915

8.  Characterization of a novel necrotic granuloma model of latent tuberculosis infection and reactivation in mice.

Authors:  Noton K Dutta; Peter B Illei; Sanjay K Jain; Petros C Karakousis
Journal:  Am J Pathol       Date:  2014-05-09       Impact factor: 4.307

Review 9.  Advancing host-directed therapy for tuberculosis.

Authors:  Robert S Wallis; Richard Hafner
Journal:  Nat Rev Immunol       Date:  2015-03-13       Impact factor: 53.106

10.  Characterization of lung inflammation and its impact on macrophage function in aging.

Authors:  Cynthia H Canan; Nandan S Gokhale; Bridget Carruthers; William P Lafuse; Larry S Schlesinger; Jordi B Torrelles; Joanne Turner
Journal:  J Leukoc Biol       Date:  2014-06-16       Impact factor: 4.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.